[go: up one dir, main page]

SK112999A3 - Phytosterol composition for preventing alzheimer's disease - Google Patents

Phytosterol composition for preventing alzheimer's disease Download PDF

Info

Publication number
SK112999A3
SK112999A3 SK1129-99A SK112999A SK112999A3 SK 112999 A3 SK112999 A3 SK 112999A3 SK 112999 A SK112999 A SK 112999A SK 112999 A3 SK112999 A3 SK 112999A3
Authority
SK
Slovakia
Prior art keywords
disease
apo
alzheimer
beta
sitosterol
Prior art date
Application number
SK1129-99A
Other languages
English (en)
Slovak (sk)
Inventor
Egon Novak
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of SK112999A3 publication Critical patent/SK112999A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1129-99A 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease SK112999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (1)

Publication Number Publication Date
SK112999A3 true SK112999A3 (en) 2001-11-06

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1129-99A SK112999A3 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Country Status (18)

Country Link
US (1) US5985936A (no)
EP (1) EP0967982A2 (no)
CN (1) CN1252724A (no)
AU (1) AU1656099A (no)
BG (1) BG103740A (no)
BR (1) BR9807577A (no)
CA (1) CA2281710A1 (no)
EE (1) EE9900354A (no)
GE (1) GEP20022783B (no)
HU (1) HUP0100737A3 (no)
LT (1) LT4801B (no)
LV (1) LV12438B (no)
MD (1) MD1920F2 (no)
NO (1) NO993979L (no)
PL (1) PL335421A1 (no)
RU (1) RU2173151C2 (no)
SK (1) SK112999A3 (no)
WO (1) WO1999032097A2 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
AU780624B2 (en) * 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
US6610320B2 (en) 2000-04-14 2003-08-26 Mars, Incorporated Compositions and methods for improving vascular health
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
EP1442133B1 (en) * 2001-02-12 2007-12-12 N.V. Organon Use of Mirtazapine for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2005208566A1 (en) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. APOE genetic markers associated with age of onset of Alzheimer's Disease
WO2006068768A2 (en) * 2004-11-24 2006-06-29 Hanna Skubatch Methods and compositions for treating conditions
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
EP2254580A1 (en) * 2008-03-27 2010-12-01 EVOTEC Neurosciences GmbH Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
WO2012149111A1 (en) * 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123617A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for reducing bcl2 gene expression
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
EP3681477A4 (en) 2017-09-14 2021-06-09 Phoenix Biotechnology, Inc. PROCEDURES AND IMPROVED COMPOSITION FOR TREATMENT OF TREITERPEN RESPONSIBLE CONDITIONS, DISEASES, OR DISORDERS
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
EP4081198A1 (en) 2019-12-24 2022-11-02 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
TJ302B (en) * 1994-09-29 2001-08-06 Univ British Columbia A process for isolating a phytosterol composition composition a product therapeutically
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
US6939570B1 (en) * 1997-05-15 2005-09-06 University Of Washington Composition and methods for treating Alzheimer's disease and other amyloidoses

Also Published As

Publication number Publication date
EP0967982A2 (en) 2000-01-05
PL335421A1 (en) 2000-04-25
LV12438A (en) 2000-03-20
GEP20022783B (en) 2002-09-25
NO993979L (no) 1999-10-13
BG103740A (en) 2000-05-31
EE9900354A (et) 2000-02-15
CA2281710A1 (en) 1999-07-01
WO1999032097A3 (en) 1999-09-02
HUP0100737A3 (en) 2002-07-29
US5985936A (en) 1999-11-16
MD1920F2 (ro) 2002-05-31
WO1999032097A2 (en) 1999-07-01
BR9807577A (pt) 2001-08-07
AU1656099A (en) 1999-07-12
MD990262A (en) 2000-06-30
HUP0100737A2 (hu) 2001-09-28
CN1252724A (zh) 2000-05-10
LV12438B (en) 2000-09-20
NO993979D0 (no) 1999-08-18
RU2173151C2 (ru) 2001-09-10
LT4801B (lt) 2001-06-25
LT99114A (lt) 2001-01-25

Similar Documents

Publication Publication Date Title
RU2173151C2 (ru) Способ и композиция для профилактики и задержки начала болезни альцгеймера
Connell et al. Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia
Salem Jr et al. The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Anil The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype
Martin et al. Brain cholesterol in normal and pathological aging
Hottman et al. HDL and cognition in neurodegenerative disorders
Leduc et al. APOE and cholesterol homeostasis in Alzheimer's disease
Vance et al. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system
Wang et al. Lipoprotein lipase in the brain and nervous system
Zhu et al. Lipid metabolism in Alzheimer’s disease
Xiao et al. DHA ameliorates cognitive ability, reduces amyloid deposition, and nerve fiber production in Alzheimer’s disease
Maria Giudetti et al. The role of brain cholesterol and its oxidized products in Alzheimer's disease
Turri et al. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
JP2004505910A (ja) アポリポタンパク質ｅ分泌を誘導するための方法
Uddin et al. Emerging therapeutic promise of ketogenic diet to attenuate neuropathological alterations in Alzheimer’s disease
Takechi et al. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease
Lovati et al. Increased plasma and aortic triglycerides in rabbits after acute administration of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
Paseban et al. The role of the ATP-binding cassette A1 (ABCA1) in neurological disorders: a mechanistic review
Kiebish et al. Chronic caloric restriction attenuates a loss of sulfatide content in PGC-1α mouse cortex: a potential lipidomic role of PGC-1α in neurodegeneration
Mas et al. Functional vitamin E deficiency in ApoE4 patients with Alzheimer’s disease
CZ9902921A3 (cs) Léčivo pro profylaxi nebo zpomalení rozvoje Alzheimerovy choroby a terapeuticky účinný produkt k prevenci Alzheimerovy choroby
MXPA99007622A (en) Method of preventing and delaying the onset of alzheimer's disease and composition therefor
Plourde Aging, cognitive decline, apolipoprotein E and docosahexaenoic acid metabolism
van Heijningen et al. Early life exposure to a diet with a supramolecular lipid structure close to that of mammalian milk improves early life growth, skeletal development, and later life neurocognitive function in individually and socially housed male C57BL/6J mice
JP2001512494A (ja) アルツハイマー病を予防するまたはその発病を遅延させる方法およびそのための組成物